Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · May 10, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called ECMO (Extracorporeal Membrane Oxygenation) for children who are experiencing severe septic shock. Septic shock is a serious condition that can cause the body's organs to stop working properly, and it remains a leading cause of death in children worldwide. The trial aims to find out if ECMO can help improve the chances of survival for these children and determine the best time to start this treatment.

To participate in this study, children must be admitted to the Pediatric Intensive Care Unit (PICU) with septic shock that does not respond to standard treatments. Unfortunately, children with certain severe conditions, like uncontrolled bleeding or significant brain damage, cannot take part. If eligible, participants will receive ECMO, which helps support their heart and lungs while doctors monitor their recovery closely. This trial is currently recruiting participants, and it is an important step in understanding how to better treat children facing this life-threatening condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Children with septic shock and refractory septic shock admitted to the PICU of all the study centers
• Exclusion Criteria:
• • Fatal chromosomal abnormalities (e.g., trisomy 13 or 18)
• • Uncontrolled bleeding
• • Irreversible brain damage
• • After allogeneic bone marrow transplantation
• • Weight less than 2.5kg or severe malnutrition